LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
Go back to LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint| Pfizer Inc. (NYSE: PFE) | Delayed: 28.57 +0.11 (0.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.46 | 52 Week High | $37.39 | |||
| Open | $28.82 | 52 Week Low | $28.25 | |||
| Day High | $29.09 | P/E | 17.32 | |||
| Day Low | $28.50 | EPS | $1.65 | |||
| Volume | 24,800,974 | |||||
